Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

FDA accepts supplemental BLA filing for Adcetris

May 15, 2013

MorphoSys begins new phase II trial of MOR-208 in NHL

May 14, 2013

Researchers develop novel vaccine with the potential to block tumor foci formation

May 14, 2013

Novel chimeric antigen receptors presented by HHS

May 13, 2013

Daratumumab receives FDA breakthrough therapy designation

May 3, 2013

MorphoSys begins phase II MOR-208 trial

April 30, 2013

Glytech designs novel cancer immunotherapeutic

April 30, 2013

Listeria-based prostate cancer vaccines developed at Aduro BioTech

April 30, 2013

European CHMP recommends conditional approval of Erivedge for BCC

April 29, 2013

Lambrolizumab designated as breakthrough therapy by the FDA

April 26, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...